Shuguang Leng1, Yushi Liu1, Joel L Weissfeld1, Cynthia L Thomas1, Younghun Han1, Maria A Picchi1, Christopher K Edlund1, Randall P Willink1, Autumn L Gaither Davis1, Kieu C Do1, Tomoko Nukui1, Xiequn Zhang1, Elizabeth A Burki1, David Van Den Berg1, Marjorie Romkes1, W James Gauderman1, Richard E Crowell1, Yohannes Tesfaigzi1, Christine A Stidley1, Christopher I Amos1, Jill M Siegfried1, Frank D Gilliland1, Steven A Belinsky2. 1. : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS). 2. : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS). sbelinsk@LRRI.org.
Abstract
BACKGROUND: Lung cancer is the leading cause of cancer-related mortality worldwide. Detection of promoter hypermethylation of tumor suppressor genes in exfoliated cells from the lung provides an assessment of field cancerization that in turn predicts lung cancer. The identification of genetic determinants for this validated cancer biomarker should provide novel insights into mechanisms underlying epigenetic reprogramming during lung carcinogenesis. METHODS: A genome-wide association study using generalized estimating equations and logistic regression models was conducted in two geographically independent smoker cohorts to identify loci affecting the propensity for cancer-related gene methylation that was assessed by a 12-gene panel interrogated in sputum. All statistical tests were two-sided. RESULTS: Two single nucleotide polymorphisms (SNPs) at 15q12 (rs73371737 and rs7179575) that drove gene methylation were discovered and replicated with rs73371737 reaching genome-wide significance (P = 3.3×10(-8)). A haplotype carrying risk alleles from the two 15q12 SNPs conferred 57% increased risk for gene methylation (P = 2.5×10(-9)). Rs73371737 reduced GABRB3 expression in lung cells and increased risk for smoking-induced chronic mucous hypersecretion. Furthermore, subjects with variant homozygote of rs73371737 had a two-fold increase in risk for lung cancer (P = .0043). Pathway analysis identified DNA double-strand break repair by homologous recombination (DSBR-HR) as a major pathway affecting susceptibility for gene methylation that was validated by measuring chromatid breaks in lymphocytes challenged by bleomycin. CONCLUSIONS: A functional 15q12 variant was identified as a risk factor for gene methylation and lung cancer. The associations could be mediated by GABAergic signaling that drives the smoking-induced mucous cell metaplasia. Our findings also substantiate DSBR-HR as a critical pathway driving epigenetic gene silencing.
BACKGROUND:Lung cancer is the leading cause of cancer-related mortality worldwide. Detection of promoter hypermethylation of tumor suppressor genes in exfoliated cells from the lung provides an assessment of field cancerization that in turn predicts lung cancer. The identification of genetic determinants for this validated cancer biomarker should provide novel insights into mechanisms underlying epigenetic reprogramming during lung carcinogenesis. METHODS: A genome-wide association study using generalized estimating equations and logistic regression models was conducted in two geographically independent smoker cohorts to identify loci affecting the propensity for cancer-related gene methylation that was assessed by a 12-gene panel interrogated in sputum. All statistical tests were two-sided. RESULTS: Two single nucleotide polymorphisms (SNPs) at 15q12 (rs73371737 and rs7179575) that drove gene methylation were discovered and replicated with rs73371737 reaching genome-wide significance (P = 3.3×10(-8)). A haplotype carrying risk alleles from the two 15q12 SNPs conferred 57% increased risk for gene methylation (P = 2.5×10(-9)). Rs73371737 reduced GABRB3 expression in lung cells and increased risk for smoking-induced chronic mucous hypersecretion. Furthermore, subjects with variant homozygote of rs73371737 had a two-fold increase in risk for lung cancer (P = .0043). Pathway analysis identified DNA double-strand break repair by homologous recombination (DSBR-HR) as a major pathway affecting susceptibility for gene methylation that was validated by measuring chromatid breaks in lymphocytes challenged by bleomycin. CONCLUSIONS: A functional 15q12 variant was identified as a risk factor for gene methylation and lung cancer. The associations could be mediated by GABAergic signaling that drives the smoking-induced mucous cell metaplasia. Our findings also substantiate DSBR-HR as a critical pathway driving epigenetic gene silencing.
Authors: Alice J Sigurdson; Irene M Jones; Qingyi Wei; Xifeng Wu; Margaret R Spitz; Douglas A Stram; Myron D Gross; Wen-Yi Huang; Li-E Wang; Jian Gu; Cynthia B Thomas; Douglas J Reding; Richard B Hayes; Neil E Caporaso Journal: Carcinogenesis Date: 2010-10-07 Impact factor: 4.944
Authors: Christopher I Amos; Xifeng Wu; Peter Broderick; Ivan P Gorlov; Jian Gu; Timothy Eisen; Qiong Dong; Qing Zhang; Xiangjun Gu; Jayaram Vijayakrishnan; Kate Sullivan; Athena Matakidou; Yufei Wang; Gordon Mills; Kimberly Doheny; Ya-Yu Tsai; Wei Vivien Chen; Sanjay Shete; Margaret R Spitz; Richard S Houlston Journal: Nat Genet Date: 2008-04-02 Impact factor: 38.330
Authors: Shuguang Leng; Christine A Stidley; Yushi Liu; Christopher K Edlund; Randall P Willink; Younghun Han; Maria Teresa Landi; Michael Thun; Maria A Picchi; Shannon E Bruse; Richard E Crowell; David Van Den Berg; Neil E Caporaso; Christopher I Amos; Jill M Siegfried; Yohannes Tesfaigzi; Frank D Gilliland; Steven A Belinsky Journal: Cancer Res Date: 2011-12-02 Impact factor: 12.701
Authors: Shuguang Leng; Kieu Do; Christin M Yingling; Maria A Picchi; Holly J Wolf; Timothy C Kennedy; William J Feser; Anna E Baron; Wilbur A Franklin; Malcolm V Brock; James G Herman; Stephen B Baylin; Tim Byers; Christine A Stidley; Steven A Belinsky Journal: Clin Cancer Res Date: 2012-04-17 Impact factor: 12.531
Authors: Shuguang Leng; Joel L Weissfeld; Maria A Picchi; Mindi A Styn; Eric D Claus; Vincent P Clark; Guodong Wu; Cynthia L Thomas; Frank D Gilliland; Jianmin Yuan; Jill M Siegfried; Steven A Belinsky Journal: Int J Mol Epidemiol Genet Date: 2016-06-01
Authors: S M Jamshedur Rahman; Xiangming Ji; Lisa J Zimmerman; Ming Li; Bradford K Harris; Megan D Hoeksema; Irina A Trenary; Yong Zou; Jun Qian; Robbert Jc Slebos; Jennifer Beane; Avrum Spira; Yu Shyr; Rosana Eisenberg; Daniel C Liebler; Jamey D Young; Pierre P Massion Journal: JCI Insight Date: 2016-11-17
Authors: Mathewos Tessema; Christin M Yingling; Maria A Picchi; Guodong Wu; Yushi Liu; Joel L Weissfeld; Jill M Siegfried; Yohannes Tesfaigzi; Steven A Belinsky Journal: J Thorac Oncol Date: 2015-08 Impact factor: 15.609
Authors: Steven A Belinsky; Shuguang Leng; Guodong Wu; Cynthia L Thomas; Maria A Picchi; Sandra J Lee; Seena Aisner; Suresh Ramalingam; Fadlo R Khuri; Daniel D Karp Journal: Cancer Prev Res (Phila) Date: 2017-09-13
Authors: Mathewos Tessema; Dereje D Tassew; Christin M Yingling; Kieu Do; Maria A Picchi; Guodong Wu; Hans Petersen; Scott Randell; Yong Lin; Steven A Belinsky; Yohannes Tesfaigzi Journal: Lung Cancer Date: 2020-05-25 Impact factor: 5.705
Authors: Shuguang Leng; Brenda Diergaarde; Maria A Picchi; David O Wilson; Frank D Gilliland; Jian-Min Yuan; Jill M Siegfried; Steven A Belinsky Journal: Am J Respir Crit Care Med Date: 2018-07-15 Impact factor: 30.528